PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

Executive Summary

• PharmaTher Holdings announced a new strategic initiative to extend its PharmaPatch™ microneedle platform into GLP‑1 therapies for obesity, targeting up‑to‑one‑month sustained drug delivery.
• The company will conduct feasibility work and preclinical evaluation, with a patent application expected later this month covering innovations from the program.
• Market opportunity highlighted: U.S. obesity treatment market projected to grow from ~$11.2 B in 2024 to ~ $48.5 B by 2030.

Key Details

• Initiative Scope: Development of a needle‑free, at‑home microneedle patch for GLP‑1 drugs aimed at obesity treatment.
• Target Delivery Profile: Potential sustained exposure up to one month from a single patch application (subject to formulation optimization and clinical validation).
• Platform Leverage: Builds on existing ketamine and psychedelic patch programs that have demonstrated controlled, sustained delivery, tolerability, and flexible dosing through patch size and drug loading.
• Intellectual Property: Finalizing a patent application for the GLP‑1 PharmaPatch™ program; filing anticipated later in January 2026.
• Market Context: CDC reports >2 in 5 U.S. adults are obese; Grand View Research estimates U.S. obesity treatment market at $11.2 B (2024) and $48.5 B (2030).
• Potential Advantages vs. Injection:
• Needle‑free administration via microneedle‑enhanced intradermal delivery.
• At‑home convenience, simplified patient experience.
• Sustained, controlled drug exposure.
• Flexible dosing through patch design variables (surface area, application time, drug loading).
• Development Timeline: Feasibility studies → preclinical evaluation; subsequent steps contingent on results and regulatory pathways.

Notable Quotes

“After advancing our ketamine and multiple psychedelic patch programs, we are now applying that platform to one of the largest and fastest‑growing opportunities in global healthcare: GLP‑1 therapy for obesity.” – Fabio Chianelli, Founder & CEO, PharmaTher Holdings Ltd.